Safer Large DNA Insertion Moves Genetic Medicine Toward Scalability

Why It Matters

INSTALL could unlock scalable, mutation‑agnostic gene therapies by removing the toxicity of double‑stranded DNA donors and reducing reliance on viral vectors, paving the way for broader treatment of complex genetic disorders.

Summary

Researchers at Massachusetts General Hospital, in partnership with Full Circles Therapeutics, have introduced a circular single‑stranded DNA donor platform called INSTALL that enables kilobase‑scale gene insertion without triggering the cGAS immune sensor. The method combines a short double‑stranded DNA segment for recombinase compatibility with a largely single‑stranded circular template, allowing non‑viral delivery via lipid nanoparticles and safe integration in mouse liver cells, whereas conventional double‑stranded donors caused fatal immune reactions. Although integration efficiency was below 1% in mice, the approach demonstrates a proof‑of‑concept for mutation‑agnostic, non‑viral large‑gene editing, addressing the toxicity and cargo‑size limits of AAV vectors. The team highlights that improving delivery to non‑dividing cells and boosting integration rates are critical next steps before clinical translation.